These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20585055)

  • 21. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.
    Ghobadi C; Johnson TN; Aarabi M; Almond LM; Allabi AC; Rowland-Yeo K; Jamei M; Rostami-Hodjegan A
    Clin Pharmacokinet; 2011 Dec; 50(12):809-22. PubMed ID: 22087867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body composition, dietary intake, and energy expenditure in nonobese, prepubertal children of obese and nonobese biological mothers.
    Francis CC; Bope AA; MaWhinney S; Czajka-Narins D; Alford BB
    J Am Diet Assoc; 1999 Jan; 99(1):58-65. PubMed ID: 9917733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature.
    Myzienski AE; Lutz MF; Smythe MA
    Pharmacotherapy; 2010 Mar; 30(3):324. PubMed ID: 20180615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Data from the StEP TWO programme showing the effect on blood pressure and different parameters for obesity in overweight and obese primary school children.
    Graf C; Rost SV; Koch B; Heinen S; Falkowski G; Dordel S; Bjarnason-Wehrens B; Sreeram N; Brockmeier K; Christ H; Predel HG
    Cardiol Young; 2005 Jun; 15(3):291-8. PubMed ID: 15865832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total and regional fat and serum cardiovascular disease risk factors in lean and obese children and adolescents.
    Teixeira PJ; Sardinha LB; Going SB; Lohman TG
    Obes Res; 2001 Aug; 9(8):432-42. PubMed ID: 11500523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of obesity on drug pharmacokinetics in humans.
    Morrish GA; Pai MP; Green B
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):697-706. PubMed ID: 21417960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a weight-loss program for obese children: a "mix of attributes" approach.
    Yin TJ; Wu FL; Liu YL; Yu S
    J Nurs Res; 2005 Mar; 13(1):21-30. PubMed ID: 15977132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug disposition in obesity: toward evidence-based dosing.
    Knibbe CA; Brill MJ; van Rongen A; Diepstraten J; van der Graaf PH; Danhof M
    Annu Rev Pharmacol Toxicol; 2015; 55():149-67. PubMed ID: 25340929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review.
    Harskamp-van Ginkel MW; Hill KD; Becker KC; Testoni D; Cohen-Wolkowiez M; Gonzalez D; Barrett JS; Benjamin DK; Siegel DA; Banks P; Watt KM;
    JAMA Pediatr; 2015 Jul; 169(7):678-85. PubMed ID: 25961828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lean body mass as a predictor of drug dosage. Implications for drug therapy.
    Morgan DJ; Bray KM
    Clin Pharmacokinet; 1994 Apr; 26(4):292-307. PubMed ID: 8013162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosing of antibacterial agents in obese adults: does one size fit all?
    Payne KD; Hall RG
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):829-54. PubMed ID: 24809811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inconsistencies in dosage practice in children with overweight or obesity: A retrospective cohort study.
    Gade C; Christensen HR; Dalhoff KP; Holm JC; Holst H
    Pharmacol Res Perspect; 2018 Jun; 6(3):e00398. PubMed ID: 29721323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control.
    Sankaralingam S; Kim RB; Padwal RS
    Can J Cardiol; 2015 Feb; 31(2):167-76. PubMed ID: 25661551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is the best size predictor for dose in the obese child?
    Anderson BJ; Holford NH
    Paediatr Anaesth; 2017 Dec; 27(12):1176-1184. PubMed ID: 29076211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding dosing: children are small adults, neonates are immature children.
    Anderson BJ; Holford NH
    Arch Dis Child; 2013 Sep; 98(9):737-44. PubMed ID: 23832061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of obesity on pharmacokinetics implications for drug therapy.
    Cheymol G
    Clin Pharmacokinet; 2000 Sep; 39(3):215-31. PubMed ID: 11020136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of drugs in obesity. An update.
    Cheymol G
    Clin Pharmacokinet; 1993 Aug; 25(2):103-14. PubMed ID: 8403734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models.
    Abduljalil K; Badhan RKS
    J Pharmacokinet Pharmacodyn; 2020 Aug; 47(4):319-340. PubMed ID: 32592111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug Dosing in Obese Children: Challenges and Evidence-Based Strategies.
    Xiong Y; Fukuda T; Knibbe CAJ; Vinks AA
    Pediatr Clin North Am; 2017 Dec; 64(6):1417-1438. PubMed ID: 29173794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Individualized dosing guidelines for children].
    Knibbe CA; Tibboel D; de Wildt SN; de Hoog M; Tjoeng MM; Danhof M
    Ned Tijdschr Geneeskd; 2013; 157(16):A4214. PubMed ID: 23594867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.